Review Article

A Systematic Review of Clinical Validated and Potential miRNA Markers Related to the Efficacy of Fluoropyrimidine Drugs

Table 4

Top 20 significant KEGG pathways enriched by fluoropyrimidine drug efficacy–related miRNAs in CRC cohorts with/without metastasis.

Without metastasisWith metastasis
KEGG pathwayGenesRatio (%) valueKEGG pathwayGenesRatio (%) value

MicroRNAs in cancer6220.009.87E-11Chronic myeloid leukemia2228.956.36E-09
FoxO signaling pathway3627.487.13E-10Cellular senescence3018.752.46E-07
Cellular senescence4025.001.21E-09TGF-beta signaling pathway2223.405.48E-07
MAPK signaling pathway5719.393.38E-09FoxO signaling pathway2619.858.85E-07
Autophagy3324.092.47E-07Non-small cell lung cancer1827.271.09E-06
Proteoglycans in cancer4220.493.02E-07MicroRNAs in cancer4313.871.31E-06
PI3K-Akt signaling pathway6016.953.1E-07Pancreatic cancer1925.001.99E-06
Hepatitis B3622.224.58E-07Signaling pathways regulating pluripotency of stem cells2618.185.82E-06
AGE-RAGE signaling pathway in diabetic complications2626.002.53E-06Pathways in cancer5911.111.22E-05
Pancreatic cancer2228.953.94E-06Proteoglycans in cancer3115.122.4E-05
Pathways in cancer7614.315.99E-06Hepatocellular carcinoma2716.074.4E-05
Colorectal cancer2326.749.64E-06Glioma1722.675.26E-05
Kaposi sarcoma-associated herpesvirus infection3719.589.82E-06Hepatitis B2616.057.44E-05
Glioma2128.001.52E-05Cell cycle2217.749.85E-05
Human cytomegalovirus infection4118.221.78E-05Prostate cancer1919.590.000119
Chronic myeloid leukemia2127.631.94E-05MAPK signaling pathway3712.590.000177
Bladder cancer1536.592.18E-05Gastric cancer2416.110.000187
Prostate cancer2424.742.41E-05AGE-RAGE signaling pathway in diabetic complications1919.000.00019

Genes related to miRNA from the two CRC cohorts were subjected to KEGG pathway enrichment analysis. The top 20 pathways with gene numbers higher than five and values less than 0.05 (corrected by the two-side Bonferroni test) were listed here.